KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Novartis Ag (NVS) EBIAT (2016 - 2025)

Historic EBIAT for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $2.4 billion.

  • Novartis Ag's EBIAT fell 1475.18% to $2.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $14.0 billion, marking a year-over-year increase of 1698.63%. This contributed to the annual value of $14.0 billion for FY2025, which is 1698.63% up from last year.
  • Latest data reveals that Novartis Ag reported EBIAT of $2.4 billion as of Q4 2025, which was down 1475.18% from $3.9 billion recorded in Q3 2025.
  • Over the past 5 years, Novartis Ag's EBIAT peaked at $16.3 billion during Q4 2021, and registered a low of $1.3 billion during Q3 2022.
  • Its 5-year average for EBIAT is $3.4 billion, with a median of $2.7 billion in 2021.
  • As far as peak fluctuations go, Novartis Ag's EBIAT surged by 67684.61% in 2021, and later crashed by 9100.94% in 2022.
  • Novartis Ag's EBIAT (Quarter) stood at $16.3 billion in 2021, then tumbled by 91.01% to $1.5 billion in 2022, then soared by 201.57% to $4.4 billion in 2023, then plummeted by 36.21% to $2.8 billion in 2024, then fell by 14.75% to $2.4 billion in 2025.
  • Its EBIAT stands at $2.4 billion for Q4 2025, versus $3.9 billion for Q3 2025 and $4.0 billion for Q2 2025.